Daratumumab for treatment-refractory acquired idiopathic pure red cell aplasia
Haematologica
.
2022 Oct 1;107(10):2523-2526.
doi: 10.3324/haematol.2022.281398.
Authors
Naseema Gangat
1
,
Jonathan Bleeker
2
,
Douglas Lynch
2
,
Horatiu Olteanu
3
,
Louis Letendre
4
,
Ayalew Tefferi
4
Affiliations
1
Division of Hematology, Mayo Clinic, Rochester, MN. gangat.naseema@mayo.edu.
2
Division of Hematology and Hematopathology, Sanford Health, Sioux Falls, SD.
3
Division of Hematopathology, Mayo Clinic, Rochester, MN.
4
Division of Hematology, Mayo Clinic, Rochester, MN.
PMID:
35678030
PMCID:
PMC9521224
DOI:
10.3324/haematol.2022.281398
No abstract available
MeSH terms
Antibodies, Monoclonal / therapeutic use
Humans
Red-Cell Aplasia, Pure* / drug therapy
Substances
Antibodies, Monoclonal
daratumumab